Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339948 | 0.87 | CA12 (0.47) | KDM4ECNR2CA12CA1CA2 | |
| SCHEMBL23930022 | 0.87 | CA12 (0.47) | KDM4ECNR2CA12CA1CA2 | |
| SCHEMBL30007781 | 0.86 | TSHR (0.43) | KDM4EALDH1A1CYP3A4CA12CA1 | |
| SCHEMBL31323187 | 0.84 | KDM4E (0.44) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL30596879 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL23930154 | 0.83 | KDM4E (0.45) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL25113893 | 0.81 | ALDH1A1 (0.49) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL23905305 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL23904747 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1CYP3A4CNR2MAPT | |
| SCHEMBL23904780 | 0.78 | KDM4E (0.43) | KDM4EALDH1A1CYP3A4CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ENANTA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12358921-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4504707-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119173505-A | Antiviral heterocyclic compounds | 英安塔制药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| WO-2024211658-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| WO-2023196454-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115461336-A | RSV inhibiting 3-substituted quinoline and cinnoline derivatives | 爱尔兰詹森科学公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357258-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885 |
| US-12358921-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885 |
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | KDM4E 3733/4885ALDH1A1 1630/4885CYP3A4 398/4885 |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ACE, HPRT1, ACE2 | KDM4E 1580/4885ALDH1A1 2104/4885CYP3A4 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.